A pharma journalist since 2017, Manas is interested in all aspects of the pharma industry and writes stories across all development phases. He may not look it, but he enjoys a mosh pit, is a beginner open-water swimmer, and loves sci-fi and fantasy.
Daraxonrasib doubles survival in pancreatic cancer, BMS puts numbers behind its CELMoD bet, and the trial count quietly falls again.
For the first time in ASCO's history, China-only data occupies the plenary slot. A hazard ratio of 0.40 in pancreatic cancer. And Lilly moving the obesity ceiling above bariatric surgery. Chicago has a lot to answer for this week.
Here is a thought experiment: where would we be if the FDA and other regulators did not allow trial flexibility?
